Detailed Information on Publication Record
2017
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
HEHLMANN, R., M. LAUSEKER, S. SAUSSELE, M. PFIRRMANN, S. KRAUSE et. al.Basic information
Original name
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
Authors
HEHLMANN, R. (276 Germany), M. LAUSEKER (276 Germany), S. SAUSSELE (276 Germany), M. PFIRRMANN (276 Germany), S. KRAUSE (276 Germany), H.J. KOLB (276 Germany), A. NEUBAUER (276 Germany), D.K. HOSSFELD (276 Germany), C. NERL (276 Germany), A. GRATWOHL (756 Switzerland), G.M. BAERLOCHER (756 Switzerland), D. HEIM (756 Switzerland), T.H. BRUMMENDORF (276 Germany), A. FABARIUS (276 Germany), C. HAFERLACH (276 Germany), B. SCHLEGELBERGER (276 Germany), M.C. MULLER (276 Germany), S. JEROMIN (276 Germany), U. PROETEL (276 Germany), K. KOHLBRENNER (276 Germany), A. VOSKANYAN (276 Germany), S. RINALDETTI (276 Germany), W. SEIFARTH (276 Germany), B. SPIESS (276 Germany), L. BALLEISEN (276 Germany), M.C. GOEBELER (276 Germany), M. HANEL (276 Germany), A. HO (276 Germany), J. DENGLER (276 Germany), C. FALGE (276 Germany), L. KANZ (276 Germany), S. KREMERS (276 Germany), A. BURCHERT (276 Germany), M. KNEBA (276 Germany), F. STEGELMANN (276 Germany), C.A. KOHNE (276 Germany), H.W. LINDEMANN (276 Germany), C.F. WALLER (276 Germany), M. PFREUNDSCHUH (276 Germany), K. SPIEKERMANN (276 Germany), W.E. BERDEL (276 Germany), L. MULLER (276 Germany), M. EDINGER (276 Germany), Jiří MAYER (203 Czech Republic, guarantor, belonging to the institution), D.W. BEELEN (276 Germany), M. BENTZ (276 Germany), H. LINK (276 Germany), B. HERTENSTEIN (276 Germany), R. FUCHS (276 Germany), M. WERNLI (756 Switzerland), F. SCHLEGEL (276 Germany), R. SCHLAG (276 Germany), M.de WIT (276 Germany), L. TRUMPER (276 Germany), H. HEBART (276 Germany), M. HAHN (276 Germany), J. THOMALLA (276 Germany), C. SCHEID (276 Germany), P. SCHAFHAUSEN (276 Germany), W. VERBEEK (276 Germany), M.J. ECKART (276 Germany), W. GASSMANN (276 Germany), A.. PEZZUTTO (276 Germany), M. SCHENK (276 Germany), P. BROSSART (276 Germany), T. GEER (276 Germany), S. BILDAT (276 Germany), E. SCHAFER (276 Germany), A. HOCHHAUS (276 Germany) and J. HASFORD (276 Germany)
Edition
Leukemia, London, Nature Publishing Group, 2017, 0887-6924
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30204 Oncology
Country of publisher
United Kingdom of Great Britain and Northern Ireland
Confidentiality degree
není předmětem státního či obchodního tajemství
Impact factor
Impact factor: 10.023
RIV identification code
RIV/00216224:14110/17:00100053
Organization unit
Faculty of Medicine
UT WoS
000414215400013
Keywords in English
chronic myeloid leukemia; imatinib
Tags
Tags
International impact, Reviewed
Změněno: 22/2/2018 18:53, Soňa Böhmová
Abstract
V originále
Chronic myeloid leukemia (CML)-study IV was designed to explore whether treatment with imatinib (IM) at 400 mg/day (n = 400) could be optimized by doubling the dose (n = 420), adding interferon (IFN) (n = 430) or cytarabine (n = 158) or using IM after IFN-failure (n = 128). From July 2002 to March 2012, 1551 newly diagnosed patients in chronic phase were randomized into a 5-arm study. The study was powered to detect a survival difference of 5% at 5 years. After a median observation time of 9.5 years, 10-year overall survival was 82%, 10-year progression-free survival was 80% and 10-year relative survival was 92%. Survival between IM400 mg and any experimental arm was not different. In a multivariate analysis, risk group, major-route chromosomal aberrations, comorbidities, smoking and treatment center (academic vs other) influenced survival significantly, but not any form of treatment optimization. Patients reaching the molecular response milestones at 3, 6 and 12 months had a significant survival advantage. For responders, monotherapy with IM400 mg provides a close to normal life expectancy independent of the time to response. Survival is more determined by patients' and disease factors than by initial treatment selection. Although improvements are also needed for refractory disease, more life-time can currently be gained by carefully addressing non-CML determinants of survival.